A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ropinirole

a non-ergoline dopamine agonist indicated for the treatment of Parkinson’s disease (PD) and moderate-to-severe primary Restless Legs Syndrome (RLS). (1.1, 1.2). 1.1 Parkinson's Disease Ropinirole t....

First FDA approval2010-02-25
Generic availableYes · 13 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$97.6M in CY2024 Part D spend5.2M claims · 1.3M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.043/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.046
Across all dosage forms in distribution.
Highest NADAC
$0.052
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Ropinirole used for?

a non-ergoline dopamine agonist indicated for the treatment of Parkinson’s disease (PD) and moderate-to-severe primary Restless Legs Syndrome (RLS). (1.1, 1.2). 1.1 Parkinson's Disease Ropinirole t....

Is there a generic for Ropinirole?

Yes. 91 ANDAs filed at FDA, 13 generic manufacturers currently shipping.

How much does my plan pay for Ropinirole?

Across 329 Part D plans, Ropinirole averages $0.046/unit (NADAC). Lowest available: $0.043/unit. Highest in distribution: $0.052/unit.

Is Ropinirole on the FDA shortage list?

No. Ropinirole is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Nonergot Dopamine Agonist2 alternatives in D1
01
Pramipexole Dihydrochloride
Nonergot Dopamine Agonist
$0.041Lowest NADAC
16Generic mfrs
CY24 Part D spend
Compare →
02
Rotigotine
Brand: Neupro
$28.21Lowest NADAC
0Generic mfrs
$128.5MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.